BioFocus Launches www.SilenceSelect.com Microsite
News Oct 05, 2009
SilenceSelect consists of over 11,500 shRNAs that can be used to knock-down approximately 5000 different human druggable targets. All of the protein classes that are considered to be affected by small molecule drugs are well represented. FLeXSelect is comprised of a collection of over 1,900 full-length human cDNAs that can be used to enhance the expression of specific genes within a cell. Using the properties of adenovirus vectors, the cDNA or shRNA is effectively delivered into a wide range of targeted human primary cells. These collections, combined with BioFocus’s unsurpassed expertise in designing disease-relevant high-content and high-throughput screening assays, serve as the basis for target discovery and mechanism of action studies. The microsite is updated daily with the latest contents of SilenceSelect and FLeXSelect, including the latest gene transcript information from NCBI.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
Scientists at McGill have found the answer to a question that perplexed Charles Darwin; if natural selection works at the level of the individual, fighting for survival and reproduction, how can a single colony produce worker ants that are so dramatically different in size – from “minor” workers to large-headed soldiers with huge mandibles – especially if they are sterile?
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019
4th Annual Congress on Nanomedicine and Drug Delivery
Apr 04 - Apr 06, 2019